Polysaccharides and glycoconjugates as human vaccines

Polysaccharides in Medicinal Applications

Volumn , Issue , 2017, Pages 443-479

  Jennings, Harold J ^a   Pon, Robert A ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; CARBOHYDRATES; DISEASE CONTROL; MAMMALS; POLYSACCHARIDES; VACCINES;

ANTIBIOTIC THERAPY; ANTIBIOTIC TREATMENT; BACTERIAL DISEASE; BACTERIAL STRAINS; CAPSULAR POLYSACCHARIDES; GLYCOCONJUGATES; INFECTIOUS DISEASE; SOLUBLE SUBSTANCES;

DISEASES;

EID: 85052605901     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203742815     Document Type: Chapter

References (200)

1. A. R. Dochez and O. T. Avery. The elaboration of specific soluble substance by pneumococcus during growth, J. Exp. Med., 26, 477, (1917).
2. M. Heidelberger and O. T. Avery, Soluble specific substance of pneumococcus, J. Exp. Med., 38, 73 (1923).
3. O. Schiemann and W. Casper, Sind die spezifisch pracipitablen Substanzen der 3 Pneumokokkentypen Haptene? Z. Hyg. Intekt. Kr., 108, 220 (1927).
4. T. Francis, Jr., and W. S. Tibet, Cutaneous reactions in pneumonia: the development of antibodies following intradermal injection of type specific polysaccharide, J. Exp. Med., 52, 573 (1930).
5. C. M. MacLeod, R. G. Hodges, M. Heidelberger, and W. G. Bernhard, Prevention of pneumococcal pneumoniae by immunization with specific capsular polysaccharides, J. Exp. Med., 82, 445 (1945).
6. M. Finland, Emergence of antibiotic resistance in hospitals, 1935-1975, Rev. Infect. Dis. 7,4(1979).
7. J. B. Robbins, Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future, Immunochemistry, 15, 839 (1978).
8. H. J. Jennings, Capsular polysaccharides as human vaccines, Adv. Carbohydr. Chem. Biochem., 41, 155 (1983).
9. H. J. Jennings, Capsular polysaccharides as vaccine candidates, Curr. Top. Microbiol. Immunol, 150, 97 (1990).
10. E. C. Gotschlich, I. Goldschneider, M. L. Lepow, and R. Gold, The immune responses to bacterial polysaccharides in man, in Antibodies in Human Diagnosis and Therapy (E. Haber and R. M. Krause, eds.), Raven Press, New York, 1977, pp. 391-402.
11. F. A. Wyle, M. S. Artenstein, B. L. Brandt, E. C. Tramont, D. L. Kasper, P. L. Altieri, S. L. Berman, and J. P. Lowenthal, Immunologic response of man to group B meningococcal polysaccharide vaccines, J. Infect. Dis., 126, 514 (1972).
12. C. J. Baker and D. L. Kasper, Group B streptococcal vaccines, Rev. Infect. Dis. 7, 458 (1985).
13. H.J. Jennings and R. K. Sood, Synthetic glycoconjugates as human vaccines, in Neoglycoconjugates: Preparation and Applications (Y. C. Lee and R. Thee, eds.), Academic Press, New York, 1994, pp. 325-371.
14. W. E. Dick, Jr., and M. Beurret, Glycoconjugates of bacterial carbohydrate antigens, in Contributions to Microbiology and Immunology, Vol. 10 (J. M. Cruse and R. E. Lewis, eds.), S. Karger, Basel, 1989, pp. 48-114.
15. J. B. Robbins and R. Schneerson, Polysaccharide-protein conjugates: a new generation of vaccines, J. Infect. Dis., 161, 821 (1990).
16. D. S. Fedson, and D. M. Musher, Pneumococcal vaccine, in Vaccines (S. A. Plotkin and E. A. Mortimer, eds.), WB Saunders, Philadelphia, 1994, p. 517.
17. Centers for Disease Control, Pneumococcal polysaccharide vaccine usage, United States, MMWR, 33, 273 (1984).
18. J. O. Klein, Otitis media, Clin. Infect. Dis., 19, 823 (1994).
19. M. Kulakowska, J. -R. Brisson, D. W. Griffith, N. M. Young, and H. J. Jennings, High-resolution NMR spectroscopic analysis of the C-polysaccharide of Streptococcus pneumoniae, Can. J. Chem., 71, 644 (1993).
20. D. S. Fedson, Pneumococcal vaccine, in Vaccines (S. A. Plotkin and E. A. Mortimer eds.), WB Saunders, Philadelphia, 1988, p. 271.
21. R. Austrian, Some observations on the Pneumococcus and on the current status of pneumococcal disease and its prevention, Rev. Infect. Dis., 3 (suppl.), S1 (1981).
22. J. B. Robbins, R. Austrian, C. J. Lee, S. C. Rastogi, G. Schiffman, J. Henrichsen, P. H. Makela, C. V. Broome, R. R. Facklam, R. H. Tiesjema, and J. C. Parke, Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups, J. Infect. Dis., 148, 1136 (1983).
23. E. Lund and J. Henrichsen, Laboratory diagnosis, serology and epidemiology of Streptococcus pneumoniae, Methods Microbiol, 12, 241 (1978).
24. W. Fischer, T. Behr, R. Hartmann, J. Peter-Katalinic, and H. Egge, Teichoic acid and lipoteichoic acid of Streptococcus pneumoniae possess identical chain structures: a reinvestigation of teichoic acid (C polysaccharide), Eur. J. Biochem., 215, 851 (1993).
25. D. E. Briles, J. L. Claflin, K. Schroer, and C. Forman, Mouse IgG3 antibodies are highly protective against infection with Streptococcus pneumoniae type 1, Nature, 294, 88 (1981).
26. D. E. Briles, M. Nahm, K. Schroer, J. Davie, P. Baker, J. Kearney, and R. Barletta, Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 Streptococcus pneumoniae, J. Exp. Med., 153, 694 (1981).
27. S. C. Szu, S. Clarke, and J. B. Robbins, Protection against pneumococcal infection in mice conferred by phosphocholine-binding antibodies: specificity of the phosphocholine binding and relation to several types, Infect. Immun., 39, 993 (1983).
28. J. J. Kenny, G. Guelde, R. T. Fischer, and D. L. Longo, Induction of phosphocholine-specific antibodies in X-linked immune deficient mice: in vivo protection against a Streptococcus pneumoniae challenge, Int. Immunol, 6, 561 (1994).
29. S. C. Szu, R. Schneerson, and J. B. Robbins, Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci, Infect. Immun., 54, 448 (1986).
30. S. V. Nielsen, U. B. S. Sorensen, and J. Henrichsen, Antibodies against pneumococcal C-polysaccharide are not protective, Microb. Pathogen., 14, 299 (1993).
31. D. M. Musher, D. A. Watson, and R. E. Baughn, Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection? J. Infect. Dis., 161, 736 (1990).
32. M. J. Fine, M. A. Smith, C. A. Carson, F. Meffe, S. S. Sankey, L. A. Weissfeld, A. S. Detsky and W. N. Kapoor, Efficacy of pneumococcal vaccination in adults, Arch. Intern. Med., 154, 2666 (1994).
33. C.-J. Lee, Bacterial capsular polysaccharides: biochemistry, immunity and vaccine, Mol. Immunol., 24, 1005 (1987).
34. H. Peltola, Meningococcal disease: still with us, Rev. Infect. Dis., 5, 71 (1983).
35. E. C. Gotschlich, Meningococcal meningitis, in Bacterial Vaccines, (E. Germanier, ed.), Academic Press, New York, 1984, pp. 237-255.
36. F. A. Riordan, O. Marzouk, A. P. J. Thomson, J. A. Sills, and C. A. Hart, Mortality from group C meningococcal disease: a case for a conjugate vaccine? Eur. J. Pediatr., 153, 821 (1994).
37. H. Peltola, K. Jonsdottir, A. Lystad, C. J. Sievers, and I. Kallings, Meningococcal disease in Scandinavia, Br. Med. J., 284, 1618 (1982).
38. J. D. Wenger, A. W. Hightower, R. R. Facklam, S. Gaventa, C. V.: Broome, and the Bacterial Meningitis Study Group, Bacterial meningitis in the United States, 1986; report of a multistate surveillance study, J. Infect. Dis., 160, 1316 (1990).
39. R. Biselli, A. Fattorossi, P. M. Matricardi, R. Nisini, T. Stroffolini, and R. D’Amelio, Dramatic reduction of meningococcal meningitis among military recruits in Italy after introduction of specific vaccination, Vaccine, 11, 578 (1993).
40. K. M. Zangwill, R. W. Stout, G. M. Carlone, L. Pais, H. Harekeh, S. Mitchell, W. H. Wolfe, V. Blackwood, B. D. Plikaytis, and J. D. Wenger, Duration of antibody response after meningococcal polysaccharide vaccination in US air force personnel, J. Infect. Dis., 169, 847 (1994).
41. H. Peltola, H. Makela, H. Kayhty, H. Jousimies, E. Herva, K. Hallstrom, A. Sivonen, O. Renkonen, O. Pettay, V. Karanko, P. Ahvoven, and S. Sarna, Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age, N. Engl. J. Med., 297, 686(1977).
42. A. L. Reingold, C. V. Broome, A. W. Hightower, G. W. Ajello, G. A. Bolan, C. Adamsbaum, E. E. Jones, C. Phillips, H. Tiendrebeogo, and A. Yada, Age specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine, Lancet, 2, 114 (1985).
43. S. J. Ceesay, S. J. Allen, A. Menon, J. E. Todd, K. Cham, G. M. Carlone, S. H. Turner, L. L. Gheesling, W. DeWitt, B. D. Plikaytis, and B. Greenwood, Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization, J. Infect. Dis., 167, 1212 (1993).
44. F. A. Troy, Polysialylation from bacteria to brains, Glycobiology, 2, 5 (1992).
45. J. -R. Brisson, H. Baumann, A. Imberty, S. Perez, and H. J. Jennings, Helical epitope of the group B meningococcal a(2-8)-linked sialic acid polysaccharide, Biochemistry, 31, 4996 (1992).
46. H. Baumann, J. -R. Brisson, F. Michon, R. Pon, and H. J. Jennings, Comparison of the conformation of the epitope of a(2-8) polysialic acid with its reduced and TV-acyl derivatives, Biochemistry, 32,4007 (1993).
47. P. Anderson, G. Peter, R. B. Johnston, L. H. Wetterlow, and D. H. Smith, Immunization of humans with polyribophosphate, the capsular antigen of Haemophilus influenzae type b, J. Clin. Invest., 51, 39 (1972).
48. H. Peltola, H. Kayhty, A. Sivonen, P. H. Makela, Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland, Pediatrics, 60, 730 (1977).
49. C. J. Baker and M. S. Edwards, Group B streptococcal infections, in Infectious Diseases of the Fetus and Newborn Infant (J. S. Remington and J. O. Klein, eds.), WB Saunders, Philadelphia, 1983, pp. 820-881.
50. D. L. Kasper, C. J. Baker, R. S. Baltimore, J. H. Crabb, G. Schiffman, and H. J. Jennings, Immuno-determinant specificity of human immunity to type III group B Streptococcus, J. Exp. Med., 149, 327 (1979).
51. D. L. Kasper and H. J. Jennings, Immunological, immunochemical and structural studies of the type III and group B streptococcal polysaccharides, in Medical Microbiology, Vol. 1 (C. S. F. Easmon and J. Jeljaszewicz, eds.), Academic Press, New York, 1982, pp. 183-216.
52. M. R. Wessels, J. L. DiFabio, V. J. Benedf, D. L. Kasper, F. Michon, J. -R. Brisson, J. Jehʼnkova, and H. J. Jennings, Structural determination and immunochemical characterization of the type V group B Streptococcus capsular polysaccharide, J. Biol. Chem., 266, 6714 (1991).
53. T. Murai, Y. Inazumi, M. Sugiyama, and Y. Nishiyama, Antigenicity and prevalence of group B Streptococcus, type M9, in Japan, Zentralbl. Bakteriol. Mikrobiol. Hyg. Abt., 1 (suppl. 22), 467 (1992).
54. H. J. Jennings, E. Katzenellenbogen, C. Lugowski, F. Michon, R. Roy and D. L. Kasper, Structure, conformation and immunology of sialic acid containing polysaccharides of human pathogenic bacteria, Pure Appl. Chem., 56, 893 (1984).
55. M. S. Edwards, D. L. Kasper, H. J. Jennings, C. J. Baker, and A. Nicholson-Weller, Capsular sialic acids prevents activation of the alternative complement pathway by type III group B Streptococcus, J. Immunol., 128, 1278 (1982).
56. L. C. Paoletti, M. R. Wessels, A. K. Rodewald, A. A. Shroff, H. J. Jennings, and D. L. Kasper, Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine, Infect. Immun., 62, 3236 (1994).
57. R. A. Insel, M. Amstey, K. Woodin, and M. Pichichero, Maternal immunization to prevent infectious diseases in the neonate or infant, Int. J. Technol. Assessment Health Care, 10, 143 (1994).
58. R. Edelman and M. M. Levine, Summary of an international workshop on typhoid fever, Rev. Infect. Dis., 8, 329(1986).
59. R. B. Hornick, Selective primary health care: strategies for control of disease in the developing world. XX. Typhoid fever, Rev. Infect. Dis., 7, 536 (1985).
60. P. D. Gulati, S. N. Saxena, P. S. Gupta, and H. K. Chuttani, Changing pattern of typhoid fever, Am. J. Med., 45, 544(1968).
61. W. T. Mahle and M. M. Levine, Salmonella typhi infection in children younger than five years of age, Pediatr. Infect. Dis. J., 12, 627 (1993).
62. J. T. La Brooy, Typhoid in 1993, Med. J. Aust., 159, 598 (1993).
63. P. R. Edwards and W. H. Ewing, Identification of Enterobacteriaceae, Burgess Publishing, Minneapolis, 1972, p. 164.
64. F. Orskov and I. Orskov, Summary of a workshop on the clone concept in the epidemiology, taxonomy, and evolution of the enterobacteriaceae and other bacteria, J. Infect. Dis., 148, 346 (1983).
65. R. H. Gilman, R. B. Hornick, W. E. Woodward, H. L. DuPont, M. J. Snyder, M. M. Levine, and J. P. Libonati, Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as live oral vaccine, J. Infect. Dis., 136, 717 (1977).
66. Requirements for Vi polysaccharide typhoid vaccine, in World Health Organization. Technical Report Series, Geneva, 1993.
67. M. M. Levine, C. Ferreccio, R. E. Black, C. O. Tacket, R. Germanier, and the Chilean Typhoid Committee, Progress in vaccines against typhoid fever, Rev. Infect. Dis., 11(S-3), S552 (1989).
68. M. Saxena, P. B. Percheson, and D. L. Di Fabio, Virulence and immunogenicity of galactose-resistant variants of Salmonella typhi Ty21a, J. Infect. Dis., 168, 522 (1993).
69. M. Saxena and J. L. Di Fabio, Salmonella typhi O-polysaccharide-tetanus toxoid conjugated vaccine, Vaccine, 12, 879(1994).
70. J. D. Robbins and J. B. Robbins, Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi, J. Infect. Dis., 150, 436 (1984).
71. I. L. Acharya, C. U. Lowe, R. Thapa, V. L. Gurubacharya, M. B. Shrestha, M. Cadoz, D. Schulz, J. Armand, D. A. Bryla, B. Trollfors, T. Cramton, R. Schneerson, and J. B. Robbins, Prevention of typhoid fever in Nepal with the Vi polysaccharide of Salmonella typhi: a preliminary report, N. Engl. J. Med., 317, 1101 (1987).
72. K. P. Klugman, I. T. Gilbertson, H. J. Koornhof, J. B. Robbins, R. Schneerson, D. Schulz, M. Cadoz, J. Armand, and the Vaccination Advisory Committee, Protective activity of Vi capsular polysaccharide vaccine against typhoid fever, Lancet, 2, 1165 (1987).
73. W. A. Keitel, N. L. Bond, J. M. Zahradnik, T. A. Cramton, and J. B. Robbins, Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines, Vaccine, 12, 195 (1994).
74. S. C. Szu, A. L. Stone, J. D. Robbins, R. Schneerson, and J. B. Robbins, Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever, J. Exp. Med., 166, 1510 (1987).
75. S. C. Szu, X. Li, R. Schneerson, J. H. Vickers, D. Bryla, and J. B. Robbins, Comparative immuno-genicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower molecular weight Vi, Infect. Immun., 57, 3823 (1989).
76. S. C. Szu, D. N. Taylor, A. C. Trofa, J. D. Clements, J. S. Shiloach, J. C. Sadoff, D. A. Bryla, and J. B. Robbins, Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines, Infect. Immun., 62, 4440 (1994).
77. K. E. Stein, Thymus-independent and thymus-dependent responses to polysaccharide antigens, J. Infect. Dis., 165 (suppl.), S49 (1992).
78. P. J. Baker, D. F. Amsbaugh, P. W. Stashak, G. Caldes, and B. Prescott, Regulation of the antibody response to pneumococcal polysaccharide by thymus-derived cells, Rev. Infect. Dis., 3, 332 (1981).
79. H. Braley-Mullen, Regulatory role of T cells in IgG antibody formation and immune memory to type III pneumococcal polysaccharide, J. Immunol., 113, 1909 (1974).
80. M. Garg, A. M. Kaplan, and S. Bondada, Cellular basis of differential responsiveness of lymph nodes and spleen to 23-valent Pnu-Immune vaccine, J. Immunol., 152, 1589 (1994).
81. R. G. Feldman, G. T. Rijkers, and B. J. M. Zegers, Human B lymphocyte in vitro response to the group B streptococcal type III capsular carbohydrate, Scand. J. Immunol., 37, 343 (1993).
82. A. W. Griffioen, E. A. H. Toebes, G. T. Rijkers, F. H. J. Claas, G. Datema, and B. J. M. Zegers, The amplifier role of T cells in the human in vitro B cell response to type 4 pneumococcal polysaccharide, Immunol. Lett, 32, 265 (1992).
83. M. G. Scott, H. G. Zachau, and M. H. Nahm, The human antibody V region repertoire to the type B capsular polysaccharide of Haemophilus influenzae, Int. Rev. Immunol, 9, 45 (1992).
84. R. H. Zubler, Antigens, T dependent and independent, in Encyclopedia of Immunology (I. M. Roitt and P. J. Delves, eds.), Academic Press, London, 1992, p. 136.
85. J. W. Yewdell and J. R. Bennink, Antigen processing: a critical factor in rational vaccine design, Semin. Hematol, 30, 26 (1993).
86. S. Lederman, M. J. Yellin, L. R. Covey, A. M. Cleary, R. Callard, and L. Chess, Non-antigen signals for B cell growth and differentiation to antibody secretion, Curr. Opin. Immunol, 5, 439 (1993).
87. G. Y. Ishioka, A. G. Lamont, D. Thomson, N. Bulbow, F. C. A. Gaeta, A. Sette, and H. M. Grey, Major histocompatibility complex class II association and induction of T cell responses by carbohydrates and glycopeptides, Springer Semin. Immunopathol,. 15, 293 (1993).
88. C. V. Harding, R. W. Roof, P. W. Allen, and E. R. Unanue, Effects of pH and polysaccharides on peptide binding to class II major histocompatibility complex molecules, Proc. Natl. Acad. Sci. USA, 88, 2740 (1991).
89. G. M. Griffiths, C. Berek, M. Kaartinen, and C. Milstein, Somatic mutation and the maturation of immune response to 2-phenyl oxazolone, Nature, 312, 271 (1984).
90. R. A. Insel and P. W. Anderson, Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants, J. Exp. Med., 163, 262 (1986).
91. R. A. Insel, E. E. Adderson, and W. L. Carroll, The repertoire of human antibody to the Haemophilus influenzae type b capsular polysaccharide, Int. Rev. Immunol, 9, 25 (1992).
92. F. H. Azmi, A. H. Lucas, H. V. Raff, and D. M. Granoff, Variable region sequences and idiotypic expression of a protective human immunoglobulin M antibody to capsular polysaccharides of Neisseria meningitidis group B and Escherichia coli K1, Infect. Immun., 62, 1776 (1994).
93. C. C. A.M. Peeters, A. J. Tenbergen-Meekes, J. T. Poolman, B. J. M. Zegers, and G. T. Rijkers, In vitro antibody response of human lymphocytes to the Haemophilus influenzae type b capsular polysaccharide, Springer Semin. Immunopathol, 15, 247 (1993).
94. H. Kayhty, J. Eskola, H. Peltola, L. Saarinen, and P. H. Makela, High antibody responses to booster doses of either Haemophilus influenzae capsular polysaccharide or conjugate vaccine after primary immunization with conjugate vaccines, J. Infect. Dis., 165 (suppl. 1), sl65 (1992).
95. D. M. Granoff, S. J. Holmes, M. T. Osterholm, J. E. McHugh, A. H. Lucas, E. L. Anderson, R. B. Belshe, J. L. Jacobs, F. Medley, and T. V. Murphy, Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines, J. Infect. Dis., 168, 663 (1993).
96. C. J. Baker, M. A. Rench, M. S. Edwards, R. J. Carpenter, B. M. Hays, and D. L. Kasper, Immunization of pregnant women with a polysaccharide vaccine of group B Streptococcus, N. Eng. J. Med., 319, 1180(1988).
97. L. J. Baraff, S. I. Lee, and D. L. Schriger, Outcomes of bacterial meningitis in children: a metaanalysis, Pediatr. Infect. Dis. J., 12, 389 (1993).
98. G. T. Rijkers, L. A. M. Sanders, and B. J. M. Zegers, Anti-capsular polysaccharide antibody deficiency states, Immunodeficiency, 5, 1 (1993).
99. W. F. Goebel and O. T. Avery, Chemo-immunological studies on conjugated carbohydrate proteins. IV. Synthesis of the p-aminobenzyl ether of the soluble specific substance of type III pneumococcus and its coupling with protein, J. Exp. Med., 54, 431 (1931).
100. W. F. Goebel, Antibacterial immunity induced by artificial antigens. II. Immunity to experimental pneumococcal infection with antigens containing saccharides of synthetic origin, J. Exp. Med., 72, 33 (1940).
101. J. W. Zigterman, J. E. van Dam, H. Snippe, F. T. Rotteveel, M. Jansze, J. M. Willers, J. P. Kamerling, and J. F. Vliegenthart, Immunogenic properties of octasaccharide-protein conjugates derived from Klebsiella serotype 11 capsular polysaccharide, Infect. Immun., 47, 421 (1985).
102. S. B. Svenson and A. A. Lindberg, Immunochemistry of Salmonella O-antigens: preparation of an octasaccharide-bovine serum albumin immunogen representative of Salmonella serogroup B O-antigen and characterization of the antibody response, J. Immunol, 120, 1750 (1978).
103. S. J. Cryz, E. Furer, A. S. Cross, A. Wegmann, R. Germanier, and J. C. Sadoff, Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin: a conjugate vaccine in humans, J. Clin. Invest., 80: 51 (1987).
104. S. Nilsson, M. Bengtsson, and T. Norberg, Solid-phase synthesis of a fragment of the capsular polysaccharide of Haemophilus influenzae type b using H-phosphonate intermediates, Proceedings of the With International Carbohydrate Symposium, Paris, 1992, p. 320.
105. E. Katzenellenbogen and H. J. Jennings, Structural determination of the capsular polysaccharide of Streptococcus pneumoniae type 19A, Carbohydr Res., 124, 235 (1983).
106. P. Anderson, Antibody responses to Haemophilus influenzae type b and diptheria toxin induced by conjugate of oligosaccharides of the type b capsule with the non-toxic protein CRM197, Infect. Immun., 39, 233 (1983).
107. L. C. Paoletti, D. L. Kasper, F. Michon, J. DiFabio, H. J. Jennings, T. D. Tosteson, and M. R. Wessels, Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates, J. Clin. Invest., 89, 203 (1992).
108. S. C. Szu, G. Zon, R. Schneerson, and J. B. Robbins, Ultrasonic irradiation of bacterial polysaccharides: characterization of the depolymerized products and some applications of the process, Carbohydr. Res., 155, 1 (1986).
109. R. K. Sood, F. Michon, J.-M. de Muys, and H. J. Jennings, Synthesis and immunogenicity in rabbits of Streptococcus pneumoniae type 14 polysaccharide-tetanus toxoid conjugates, in Proceedings of the Xllth International Carbohydrate Symposium, Paris, 1992, p. 370.
110. E. C. Beuvery, R. Roy, V. Kanhai, and H. J. Jennings, Characteristics of two types of meningococcal group C polysaccharide conjugates using tetanus toxoid as carrier protein, Dev. Biol. Standard, 65, 197 (1986).
111. P. W. Anderson, M. E. Pichichero, R. A. Insel, R. Betts, R. Eby, and D. H. Smith, Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of Haemophilus influenzae type b coupled to a protein carrier: structural and temporal requirements for priming of the human infants, J. Immunol., 137, 1181 (1986).
112. S. Marburg, D. Jorn, R. L. Tolman, B. Arison, J. McCauley, P. J. Kniskern, A. Hagopian, and P. P. Vella, Biomolecular chemistry of macromolecules: synthesis of bacterial polysaccharide conjugates with Neisseria meningitidis membrane protein, J. Am. Chem. Soc, 108, 5282 (1986).
113. M. R. Wessels, L. C. Paoletti, D. L. Kasper, J. L. DiFabio, F. Michon, K. Holmes, and H. J. Jennings, Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus, J. Clin. Invest., 86, 1428 (1990).
114. B. A. Schwartz and G. R. Gray, Proteins containing reductively aminated disaccharides: synthesis and chemical characterization, Arch. Biochem. Biophys., 181, 542 (1977).
115. H.J. Jennings and C. Lugowski, Immunochemistry of group A, B and C meningococcal polysaccharide-tetanus toxoid conjugates, J. Immunol., 127, 1011 (1981).
116. M. Porro, P. Costantino, S. Viti, F. Vanozzi, A. Naggi, and G. Torri, Specific antibodies to diptheria toxin and type 6A pneumococcal capsular polysaccharide induced by a model of semi-synthetic glycoconjugate antigen, Mol. Immunol, 22, 907 (1985).
117. R. Schneerson, O. Barrera, A. Sutton, and J. B. Robbins, Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates, J. Exp. Med., 152, 361 (1980).
118. M. A. Liu, A. Friedman, A. I. Oliff, J. Tai, D. Martinez, R. R. Deck, J. T. C. Shieh, T. D. Jenkins, J. J. Donnelly, and L. A. Hawe, A vaccine carrier derived from Neisseria meningitidis with mitogenic activity for lymphocytes, Proc. Natl. Acad. Sci. USA, 89, 4633 (1992).
119. A Fattom, J. Shiloach, D. Bryla, D. Fitzgerald, I. Pastan, W. W. Karakawa, J. B. Robbins, and R. Schneerson, Comparative immunogenicity of conjugates composed of Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or/V-succinimidyl-3-(2-pyridyldithio)propionate, Infect. Immun., 60, 584 (1992).
120. J. C. Paton, R. A. Lock, C. -J. Lee, J. P. Li, A. M. Berry, T. J. Mitchell, P. W. Andrew, D. Hansman, and G. J. Boulnois, Purification and immunogenicity of genetically toxoided derivatives of pneumolysin and their conjugation to Streptococcus pneumoniae type 19F polysaccharide, Infect. Immun., 59, 2297 (1991).
121. Immunization Practices Advisory Committee, Update: prevention of Haemophilus influenzae type b disease, MMWR, 7, 13 (1988).
122. Centers for Disease Control, Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older, MMWR, 40 (RR-1), 1 (1991).
123. Centers for Disease Control and Prevention, FDA approval of use of a new Haemophilus influenzae b conjugate vaccine and a combined diptheria-tetanus-pertussis and Haemophilus b conjugate vaccine for infants and children, JAMA, 269, 2359 (1993).
124. M. D. Decker, K. M. Edwards, R. Bradley, and P. Palmer, Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines, J. Pediatr., 120, 184 (1992).
125. J. Ward, G. Brenneman, G. W. Letson, and W. L. Hey ward, Limited efficacy of a Haemophilus influenzae type b vaccine in Alaska Native infants, N. Engl. J. Med., 323, 1393 (1990).
126. J. Eskola, H. Kayhty, A. K. Takala, H. Peltola, P. R. Ronnberg, E. Kela, E. Pekkanen, P. H. McVerry, and P. H. Makela, A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease, N. Eng. J. Med., 323, 1381 (1990).
127. D. M. Ambrosino, D. Bolon, H. Collard, R. van Etten, M. V. Kanchana, and R. W. Finberg, Effect of Haemophilus influenzae polysaccharide outer membrane protein complex conjugate vaccine on macrophage, J. Immunol, 149, 3978 (1992).
128. P. W. Anderson, M. E. Pichichero, K. Edwards, C. R. Porch, and R. Insel, Priming and induction of Haemophilus influenzae type b capsular antibodies in early infancy by Dpo20, an oligosaccharide-protein conjugate vaccine, J. Pediatr., III, 644 (1987).
129. L. H. Harrison, C. Tajkowski, J. Croll, R. Reid, D. Hu, G. Brenneman, R. C. Weatherholtz, and M. Santosham. Postlicensure effectiveness of the Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer-membrane protein complex conjugate vaccine among Navajo children, J. Pediatr., 125, 571 (1994).
130. T. Barington, M. Skettrup, L. Juul, and C. Heilmann, Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components, Infect. Immun., 61, 432 (1993).
131. T. Barington, A. Gyhrs, K. Kristensen, and C. Heilmann, Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine, Infect. Immun., 62, 9 (1994).
132. D. M. Granoff, S. J. Holmes, R. B. Belshe, M. T. Osterholm, J. E. McHugh, and E. L. Anderson, Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants, JAMA, 272, 1116 (1994).
133. J. D. Clemens, C. Ferreccio, M. M. Levine, I. Horowitz, M. R. Rao, K. M. Edwards, and B. Fritzell, Impact of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diptheria-tetanus-pertussis vaccine, JAMA, 267, 673 (1992).
134. A. Avendano, C. Ferreccio, R. Lagos, I. Horwitz, M. Cayazzo, B. Fritzell, C. Meschievitz, and M. Levine, Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine does not depress serologic responses to diptheria, tetanus, or pertussis antigens when coadministered in the same syringe with diptheria-tetanus-pertussis vaccine at two, four, and six months of age, Pediatr. Infect. Dis. J., 12, 638 (1993).
135. S. B. Black, H. R. Shinefield, P. Ray, E. M. Lewis, B. Fireman, R. Hiatt, Kaiser Permanente Pediatric Vaccine Study Group, D. V. Madore, C. L. Johnson, and J. G. Hackell, Safety of combined oligosaccharide conjugate Haemophilus influenzae type b (HbOC) and whole cell diptheria-tetanus-pertussis vaccine in infancy, Pediatr. Infect. Dis. J., 12, 981 (1993).
136. A. Kovel, E. R. Wald, N. Guerra, C. Serdy, and C. K. Meschievitz, Safety and immunogenicity of acellular diptheria-tetanus-pertussis and Haemophilus conjugate vaccines given in combination or at separate injection sites, J. Pediatr., 120, 84 (1992).
137. H. Shinefield, S. Black, T. Adelman, and K. Ensor, Safety and immunogenicity of DTaP-HbOC: a combined oligosaccharide conjugate (HbOC, HibTITER) Haemophilus influenzae type b and acellular DTP vaccine (CTaP) in toddlers, in Proceedings from the Thirty-Second Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California, 1992, #306.
138. K. C. Schoendorf, W. G. Adams, J. L. Kiely, and J. D. Wenger, National trends in Haemophilus influenzae meningitis mortality and hospitalization among children, 1980 through 1991, Pediatrics, 93, 663 (1994).
139. Centers for Disease Control and Prevention, Progress toward elimination of Haemophilus influenzae type b disease among infants and children: United States, 1987-1993, JAMA, 271, 1231 (1994).
140. C. M. Vadheim. D. P. Greenberg, E. Eriksen, L. Hemenway, N. Bendana, L. Mascola, J. I. Ward, and the Kaiser-UCLA Vaccine Study Group, Eradication of Haemophilus influenzae type b disease in Southern California, Arch. Pediatr. Adolesc. Med, 148, 51 (1994).
141. T. V. Murphy, P. Pastor, F. Medley, M. T. Osterholm, and D. M. Granoff, Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine, J. Pediatr., 122, 517 (1993).
142. J. C. Mohle-Boetani. G. Ajello, E. Brenneman, K. A. Deaver, C. Harvey, B. D. Plikaytis, M. M. Farley, D. S. Stephens, and J. D. Wenger, Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccines, Pediatr. Infect. Dis. J., 12, 589 (1993).
143. A. K. Takala, J. Eskola, M. Leinonen, H. Käyhty, A. Nissinen, E. Pekkanen and P. H. Makela, Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with Hib conjugate vaccine, J. Infect. Dis., 164, 982 (1991).
144. E. D. Shapiro and R. Austrian, Serotypes responsible for invasive Streptococcus pneumoniae infections among children in Connecticut, J. Infect. Dis., 169, 212 (1994).
145. G. S. Giebink, C. T. Alward, A. A. Rzepka, K. Daly, and C. L. Liebeler, Isotype antibody responses to type 6B pneumococcal polysaccharide conjugate vaccine in infants, Pediatr. Res., 33, 168A (1993).
146. H. L. Keyserling, E. L. Anderson, and J. T. Martin, Immunogenicity of a tetravalent (types 6B, 14, 19F, 23F) pneumococcal conjugate vaccine in infants, Pediatr. Res., 33, 172A(1993).
147. L. C. Paoletti, M. R. Wessels, F. Michon, J. DiFabio, H. J. Jennings, D. L. Kasper, Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine, Infect. Immun., 60, 4009 (1992).
148. S. J. N. Devi, J. B. Robbins, and R. Schneerson, Antibodies to poly[(2→ 8)-α-N-acetylneuraminic acid] and poly(2→ 9)-α-N-acetylneuraminic acid are elicited by immunization of mice with Escherichia coli K-92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1, Proc. Natl. Acad. Sci. USA, 88, 7175 (1991).
149. H. J. Jennings, R. Roy, and A. Gamian, Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine, J. Immunol., 137 1708 (1986).
150. H. J. Jennings, A. Gamian, and F. E. Ashton, N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis, J. Exp. Med, 165, 1207 (1987).
151. H.J. Jennings, J.-R. Brisson, M. Kulakowska, and F. Michon, Polysialic acid vaccines against meningitis cause by Neisseria meningitidis and Escherichia coli K1, in Polysialic Acid: From Microbes to Man (J. Roth, U. Rutishauser, and F. A. Troy, eds.), Birkhauser Verlag, Basel, 1993, pp. 25-38.
152. H. J. Jennings, The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development, in Contributions to Microbiology and Immunology, Vol. 10 (J. M. Cruse and R. E. Lewn, Jr., eds.), S. Karger, Basel. 1989, pp. 151-165.
153. J. C. De Moraes, B. A. Perkins, M. C. C. Camargo, N. T. R. Hidalgo, H. A. Barbosa, C. T. Sacchi, I. M. L. Gral, V. L. Gattas, H. G. Vasconcelos, B. D. Plikaytis, J. D. Wenger, and C. V. Broome, Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil, Lancet, 340, 1074 (1992).
154. W. D. Zollinger, J. Boslego, E. Moran, J. Garcia, S. Ruiz, B. Brandt, M. Martinez, J. Arthur, P. Underwood, W. Hankins, J. Mays, J. Gilly, and the Chilean National Committee for Meningococcal Disease, Meningococcal serogroup B vaccine: protection trial and follow up studies in Chile, NIPH Ann., 74, 211 (1991).
155. G. Bjune, E. A. Hoiby, J. K. Gronnesby, O. Arnesen, J. H. Frederiksen, A. Halstensen, E. Holten, A.-K Lindbak, H. Nokleby, E. Rosenquist, L. K. Solberg, O. Closs, J. Eng., L. O. Froholm, A. Lystad, L. S. Bakketeig, and B. Hareide, Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway, Lancet, 338, 1093 (1991).
156. E. Rosenqvist, E. A. Hoiby, E. Wedege, D. A. Caugant, L. O. Froholm, B. T. McGuiness, J. Brooks, P. R. Lambden, and J. E. Heckels, A new variant of serosubtype P1.16 in Neisseria meningitidis from Norway, associated with increased resistance to bactericidal antibodies induced by a serogroup B outer membrane protein vaccines, Microbial Pathogenesis, 15, 197 (1993).
157. E. L. Anderson, T. Bowers, C. M. Mink, D. L. Kennedy, R. B. Belshe, H. Harakeh, L. Pais, P. Holder, and G. M. Carlone, Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults, Infect. Immun., 62, 3391 (1994).
158. P. Costantino, S. Viti, A. Podda, M. A. Velmonte, L. Nencioni, and R. Rappuoli, Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C, Vaccine, 10, 691 (1992).
159. B. Lindberg, B. Lindqvist, J. Lönngren, and D. A. Powell, Structural studies of the capsular polysaccharide from Streptococcus pneumoniae type 1, Carbohydr. Res., 78, 111 (1980).
160. P. E. Jansson, B. Lindberg, M. Anderson, U. Lindqvist, and J. Henrichsen, Structural studies of the capsular polysaccharide of Streptococcus pneumoniae type 2, a reinvestigation, Carbohydr. Res., 182, 111 (1988).
161. R. E. Reeves and W. F. Goebel, Chemoimmunological studies on the soluble specific substrate of pneumococcus. V. The structure of the type III polysaccharide, J. Biol. Chem., 139, 511 (1941).
162. P. E. Jansson, B. Lindberg, and U. Lindquist, Structural studies of the capsular polysaccharide from Streptococcus pneumoniae type 4, Carbohydr. Res., 95, 73 (1981).
163. P. E. Jansson, B. Lindberg, and U. Lindquist, Structural studies of the capsular polysaccharide from Streptococcus pneumoniae type 5, Carbohydr. Res., 140, 101 (1985).
164. L. Kenne, B. Lindberg, and J. K. Madden, Structural studies on the capsular antigen from Streptococcus pneumoniae type 26, Carbohydr. Res., 73, 175 (1979).
165. M. Moreau, J. C. Richards, M. B. Perry, and K. J. Kniskern, Application of high resolution nuclear magnetic resonance spectroscopy to the structural elucidation of the specific capsular polysaccharide of Streptococcus pneumoniae type 7F, Carbohydr. Res., 182, 79 (1988).
166. J. K. N. Jones and M. B. Perry, The structure of the type VIII pneumococcus specific polysaccharide, J. Am. Chem. Soc, 79, 2787 (1957).
167. C. Jones, B. Mulloy, A. Wilson, A. Dell, and J. E. Oates, Structure of the capsular polysaccharide from Streptococcus pneumoniae type 9, J. Chem. Soc. Perkin Trans., 1, 1665 (1985).
168. M. B. Perry, V. Daoust, D. J. Carlo, The specific capsular polysaccharide of Streptococcus pneumoniae type 9V, Can. J. Biochem., 59, 524 (1981).
169. C. Jones, Full assignment of the NMR spectrum of the capsular polysaccharide from Streptococcus pneumoniae serotype 10A, Carbohydr. Res., 269, 175 (1995).
170. J. C. Richards, M. B. Perry, and M. Moreau, Elucidation and comparison of the specific capsular polysaccharides of Streptococcus pneumoniae group 11 (11F, 11B, 11C, and 11 A), Adv. Exp. Med. Biol., 228, 595 (1988).
171. K. Leontein, B. Lindberg, and J. Lönngren, Structural studies of the capsular polysaccharide from Streptococcus pneumoniae type 12F, Can. J. Chem., 59, 2081 (1981).
172. B. Lindberg, J. Lönngren, and D. A. Powell, Structural studies on the specific type 14 pneumococcal polysaccharide, Carbohydr. Res., 58, 177 (1977).
173. P. E. Jansson, B. Lindberg, U. Lindquist, and J. Ljungberg, Structural studies of the capsular polysaccharide from Streptococcus pneumoniae types 15B and 15C, Carbohydr. Res., 162, 111 (1987).
174. M. B. Perry, D. R. Bundle, V. Daoust, and D. J. Carlo, The structure of the specific polysaccharide of Streptococcus pneumoniae type 17F, in press.
175. C. Lugowski and H. J. Jennings, Structural determination of the capsular polysaccharide of Streptococcus pneumoniae type 18C (56), Carbohydr. Res., 131, 119 (1984).
176. H. J. Jennings, K.-G. Rosell, and D. J. Carlo, Structural determination of the capsular polysaccharide of Streptococcus pneumoniae type 19 (19F), Can. J. Chem., 58, 1069 (1980).
177. J. C. Richards, M. B. Perry, D. J. Carlo, The specific capsular polysaccharide of Streptococcus pneumoniae type 20, Biochem. Cell Biol., 67, 178 (1983).
178. J. C. Richards, M. B. Perry, and P. J. Kniskern, Structural analysis of the specific capsular polysaccharides of Streptococcus pneumoniae type 22F, Can J. Chem., 67, 1038 (1989).
179. J. C. Richards and M. B. Perry, Structure of the specific capsular polysaccharide of Streptococcus pneumoniae type 23F, Biochem. Cell. Biol., 66, 758 (1988).
180. J. C. Richards, M. B. Perry, and P. J. Kniskern, The specific capsular polysaccharide of Streptococcus pneumoniae 33F, Can. J. Biochem. Cell Biol., 62, 666 (1981).
181. D. R. Bundle, I. C. P. Smith, and H. J. Jennings, Determination of the structure and conformation of bacterial polysaccharides by carbon-13 nuclear magnetic resonance, J. Biol. Chem., 249, 2275 (1974).
182. A. K. Bhattacharjee, H. J. Jennings, C. P. Kenny, A. Martin, and I. C. P. Smith, Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroup B and serogroup C with carbon 13 nuclear magnetic resonance, J. Biol. Chem., 250, 1926 (1975).
183. A. K. Bhattacharjee, H. J. Jennings, A. Martin, and I. C. P. Smith, Structural determination of the polysaccharide antigens of Neisseria meningitidis serogroups Y, W-135 and BO, Can. J. Biochem., 54, 1 (1976).
184. R. M. Crisel, R. S. Baker, and D. E. Dorman, Capsular polymer of Haemophilus influenzae type b. Part 1. Structural characterization of the capsular polymer of strain Eagan, J. Biol. Chem., 250, 4926 (1975).
185. K. Heyns, G. Kiessling, W. Lindenberg, H. Paulsen, and M. E. Webster, D-Galaktosaminuornsaure (2-amino-2-desoxy-D-galakturonsaure) als baustein des Vi-antigens, Chemische Berichte, 92, 2435 (1959).
186. H. J. Jennings, K. -G. Rosell, and D. L. Kasper, Structure of native polysaccharide antigens of types la and lb group B Streptococcus, Biochemistry, 22, 1258 (1983).
187. H.J. Jennings, K. -G. Rosell, E. Katzenellenbogen, and D. L. Kasper, Structural determination of the capsular polysaccharide antigen of type II group B Streptococcus, J. Biol. Chem., 258, 1793 (1983).
188. M. R. Wessels, V. Pozsgay, D. L. Kasper, and H. J. Jennings, Structure and immunochemistry of an oligosaccharide repeating unit of the capsular polysaccharide of type III group B Streptococcus, J. Biol. Chem., 262, 8262 (1987).
189. J. L. DiFabio, F. Michon, J.-R. Brisson, H. J. Jennings, M. R. Wessels, V. J. Benedi, and D. L. Kasper, Structure of the capsular polysaccharide antigen of type IV group B Streptococcus, Can. J. Chem., 67, 877 (1989)
190. G. Kogan, D. Uhrin, J.-R. Brisson, L. C. Paoletti, D. L. Kasper, C. von Hunolstein, G. Orefici, and H. J. Jennings, Structure of the type VI group B Streptococcus capsular polysaccharide determined by high resolution NMR spectroscopy, J. Carbohydr. Chem., 13, 1071 (1994).
191. C. Chu, R. Schneerson, J. B. Robbins, and S. C. Rastagi, Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates, Infect. Immun., 40, 245 (1983).
192. B. Arndt and M. Porro, Strategies for type-specific glycoconjugate vaccines of Streptococcus pneumoniae, Adv. Exp. Med. Biol, 303, 129 (1991).
193. R. Schneerson, J. B. Robbins, J. B. Chu, A. Sutton, W. Vann, J. C. Vickers, W. T. London, B. Curf-man, M. C. Hardegree, J. Shiloach, and S. C. Rastogi, Serum antibody response of juvenile and infant Rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates, Infect. Immun., 45, 582 (1984).
194. R. Schneerson, J. B. Robbins, J. C. Parke, C. Bell, J. J. Schlessman, A. Sutton, Z. Wang, G. Schiffman, G. Karpas, and J. Shiloach, Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates, Infect. Immun., 52, 519 (1986).
195. C. H. Lu, C. J. Lee, and P. Kind, Immune responses of young mice to pneumococcal type 9V polysaccharide-tetanus toxoid conjugate, Infect. Immun., 62, 2754 (1994).
196. R. Schneerson, L. Levi, J. B. Robbins, D. M. Bryla, G. Schiffman, and T. Lagergard, Synthesis of a conjugate vaccine composed of pneumococcus type 14 capsular polysaccharide bound to pertussis toxin, Infect. Immun., 60, 3528 (1992).
197. H. J. Jennings and R. Roy, Enhancement of the immune response to the group B polysaccharide of Neisseria meningitidis by means of its chemical modification, in The Pathogenic Neisseriae (School-nik, ed.), American Society for Microbiology, Washington, D.C., 1985, p. 628.
198. M. Porro, P. Constantino, F. Giovannoni, V. Pellegrini, L. Tagliaferri, F. Vannozzi, and F. Viti, A molecular model of artificial glycoprotein with predetermined multiple immunodeterminants for gram-positive and gram-negative encapsulated bacteria, Mol. Immunol., 23, 385 (1986).
199. T. Lagergard, J. Shiloach, J. B. Robbins, and R. Schneerson, Synthesis and immunological properties of conjugates composed of Group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid, Infect. Immun., 58, 687 (1990).
200. M. R. Wessels, L. C. Paoletti, A. K. Rodewald, F. Michon, J. DiFabio, H. J. Jennings, and D. L. Kasper, Stimulation of protective antibodies against type la and lb group B streptococci by a type la polysaccharide-tetanus toxoid conjugate vaccine, Infect. Immun., 61, 4760 (1993)